- Home
- NAAS vs HCWB Comparison
NAAS vs HCWB Comparison
Compare NAAS & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAAS
- HCWB
- Stock Information
- Founded
- NAAS 2019
- HCWB 2018
- Country
- NAAS China
- HCWB United States
- Employees
- NAAS N/A
- HCWB N/A
- Industry
- NAAS Other Specialty Stores
- HCWB Biotechnology: Pharmaceutical Preparations
- Sector
- NAAS Consumer Discretionary
- HCWB Health Care
- Exchange
- NAAS Nasdaq
- HCWB Nasdaq
- Market Cap
- NAAS 18.9M
- HCWB 17.2M
- IPO Year
- NAAS 2017
- HCWB 2021
- Fundamental
- Price
- NAAS $1.63
- HCWB $0.39
- Analyst Decision
- NAAS
- HCWB
- Analyst Count
- NAAS 0
- HCWB 0
- Target Price
- NAAS N/A
- HCWB N/A
- AVG Volume (30 Days)
- NAAS 4.4M
- HCWB 18.3M
- Earning Date
- NAAS 03-27-2025
- HCWB 03-31-2025
- Dividend Yield
- NAAS N/A
- HCWB N/A
- EPS Growth
- NAAS N/A
- HCWB N/A
- EPS
- NAAS N/A
- HCWB N/A
- Revenue
- NAAS $43,258,393.00
- HCWB $3,495,990.00
- Revenue This Year
- NAAS $19.53
- HCWB $229.19
- Revenue Next Year
- NAAS $151.36
- HCWB N/A
- P/E Ratio
- NAAS N/A
- HCWB N/A
- Revenue Growth
- NAAS 50.34
- HCWB 22.27
- 52 Week Low
- NAAS $1.30
- HCWB $0.21
- 52 Week High
- NAAS $34.20
- HCWB $2.52
- Technical
- Relative Strength Index (RSI)
- NAAS 51.51
- HCWB 48.72
- Support Level
- NAAS $1.32
- HCWB $0.38
- Resistance Level
- NAAS $1.95
- HCWB $0.42
- Average True Range (ATR)
- NAAS 0.24
- HCWB 0.09
- MACD
- NAAS 0.03
- HCWB -0.00
- Stochastic Oscillator
- NAAS 27.05
- HCWB 4.48
About NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators. wide range of offline services that simplify the daily operations of charging station operators, and of non-charging services such as food and beverage services to station operators.
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.